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Background: Myxomatous mitral valve disease (MMVD) is an important cause of morbidity and mortality in dogs.
Objectives: To compare, throughout the period of follow-up of dogs that had not yet reached the primary endpoint,
the longitudinal effects of pimobendan versus benazepril hydrochloride treatment on quality-of-life (QoL) variables, con-
comitant congestive heart failure (CHF) treatment, and other outcome variables in dogs suffering from CHF secondary to
MMVD.
Animals: A total of 260 dogs in CHF because of MMVD.
Methods: A prospective single-blinded study with dogs randomized to receive pimobendan (0.4–0.6 mg/kg/day) or
benazepril hydrochloride (0.25–1.0 mg/kg/day). Differences in outcome variables and time to intensification of CHF treat-
ment were compared.
Results: A total of 124 dogs were randomized to pimobendan and 128 to benazepril. No difference was found between
groups in QoL variables during the trial. Time from inclusion to 1st intensification of CHF treatment was longer in the
pimobendan group (pimobendan 98 days, IQR 30–276 days versus benazepril 59 days, IQR 11–121 days; P = .0005).
Postinclusion, dogs in the pimobendan group had smaller heart size based on VHS score (P = .013) and left ventricular
diastolic (P = .035) and systolic (P = .0044) dimensions, higher body temperature (P = .030), serum sodium (P = .0027),
and total protein (P = .0003) concentrations, and packed cell volume (P = .030). Incidence of arrhythmias was similar in
treatment groups.
Conclusions and Clinical Importance: Pimobendan versus benazepril resulted in similar QoL during the study, but con-
ferred increased time before intensification of CHF treatment. Pimobendan treatment resulted in smaller heart size, higher
body temperature, and less retention of free water.
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Myxomatous mitral valve disease (MMVD) iscommon and continues to be an important
cause of morbidity and mortality in older small breed
dogs.1–3 We and others have demonstrated that
treatment can prolong the survival of dogs with
congestive heart failure (CHF) secondary to this condi-
tion.4,5 The ideal treatment should both lengthen life
and allow the dog to enjoy a good quality of life
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(QoL). Quality of life and survival will be closely
linked in veterinary patients where owners are more
likely to opt for the euthanasia of their pet when they
consider the pet’s QoL to be intolerable. When asked,
the majority of owners indicate that they would priori-
tize QoL of their pet over its survival time.6 Clinicians
will modify medication to optimize the QoL of the
patients they are treating.
There are problems in attempting to compare QoL
between groups. Quality of life and clinical heart failure
scores are inherently subjective. The ability of survival
studies to demonstrate differences between groups of
patients is further impaired by different rates of dropout
in treatment groups.7–10 If a dog has reached the pri-
mary endpoint of a study, or has been withdrawn for
other reasons, and continuation in the study is no longer
possible, it can no longer contribute data to longitudinal
analyses. This results in missing data, and studies have
differed in how they deal with this problem. Many stud-
ies use the approach of either “last observation carried
forward” or “worst observation carried forward,” but
this approach tends to make the treatment with the
higher dropout rate appear worse.
Heart disease and heart failure are known to lead to
changes in clinical, laboratory, radiographic, and echo-
cardiographic variables. Monitoring these variables in
dogs undergoing treatment for heart failure is a com-
mon practice and recommended in the ACVIM con-
sensus statement.11 The comparative effects of
angiotensin-converting enzyme inhibitors (ACEI) and
pimobendan on some of these variables have not been
described, and for others they have only been
described for periods of 6 months or less.9,10
We previously have reported results from the
QUEST study showing that pimobendan treatment
was associated with improved survival when compared
with benazepril treatment.5 However, we have not
reported the results with respect to the secondary out-
come variables of QoL or described comparisons
between groups for the clinical data acquired longitu-
dinally. The aims of this study were to compare the
longitudinal effects of pimobendan treatment on QoL
indices, concomitant treatment, and clinical, labora-
tory, echocardiographic, and radiographic variables
with those of a positive control (benazepril hydrochlo-
ride) in dogs diagnosed with CHF secondary to
MMVD.
Materials and Methods
We previously have described in detail the materials and meth-
ods of this study.5 Pertinent details are repeated here.
Dogs
Client-owned dogs were recruited at 28 centers in Europe,
Canada, and Australia. The study terminated on 31 October
2006.
Enrollment Criteria
Inclusion Criteria. Dogs were eligible for inclusion in the study
provided the owner had given informed consent. To be eligible
for inclusion at the time of the 1st examination, the dog must
have been >5 years of age, weighed between 5 and 20 kg, had a
characteristic heart murmur of moderate to high intensity with
maximal intensity over the mitral area, had echocardiographic
evidence of advanced MMVD defined as characteristic valvular
lesions of the mitral valve apparatus (leaflet thickening, valve
prolapse), demonstrated mitral regurgitation on color Doppler
echocardiography, had echocardiographic evidence of moderate
to severe left atrial, left ventricular enlargement, or both (ie, left
atrial to aortic root [LA/Ao] ratio >1.512 and left ventricular
internal diameter in diastole [LVIDd] values above normal refer-
ence range13), and demonstrated current or prior radiographic
evidence of pulmonary edema and cardiomegaly (ie, vertebral
heart scale [VHS] >10.5).14 Clinical signs of decompensated CHF
must have been present at the time of the 1st examination or
have previously been resolved with treatment (that must have
included furosemide) that was still being administered and in the
opinion of the attending clinician necessary to prevent the return
of clinical signs.
Exclusion Criteria. Dogs were excluded from the study if they
had a clinically relevant cardiac disease (congenital or acquired)
other than mitral regurgitation secondary to MMVD, had
another relevant systemic disease, or had evidence of other clini-
cally relevant organ dysfunction.
Study Design
Randomization and Allocation. This was a prospective multi-
center, single-blinded, positive-controlled study.
Investigators, study monitors, and the sponsor remained
blinded for the duration of the study. Unblinding occurred only
after completion of the study and data entry.
Abbreviations:
ACE-I angiotensin-converting enzyme inhibitor
ACVIM American College of Veterinary Internal Medicine
AF atrial fibrillation
AUC area under curve
BPM beats per minute
BW body weight
CHF congestive heart failure
FS fractional shortening
HF heart failure
IQR interquartile range
K potassium
LA/Ao left atrial to aortic root ratio
LVIDd inc percentage increase in LVIDd from expected values
LVIDd left ventricular internal diameter in diastole
LVIDs inc percentage increase in LVIDs from expected values
LVIDs left ventricular internal diameter in systole
MMVD myxomatous mitral valve disease
Na sodium
NYHA New York Heart Association
PCV packed cell volume
PE pulmonary edema
QoL quality of life
SVPC supraventricular premature complex
TPC total protein concentration
VHS vertebral heart scale
VPC ventricular premature complex
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Blinding. In each center, the blinding of the investigator was
ensured by the use of a dispenser. At inclusion and before each
visit, the owner was instructed to discuss test treatments with the
dispenser only. Drugs were dispensed by the dispenser in opaque
boxes to prevent inadvertent disclosure of the treatment group to
the investigator.
Test Treatments. The pimobendan group received pimoben-
dana PO at a dosage of 0.4–0.6 mg/kg/day. The calculated daily
dose was divided into 2 and adjusted to a suitable number of
1.25 or 2.5 mg capsules. Owners were instructed to administer
the drug in the morning and evening, approximately 12 hours
apart, and approximately 1 hour before feeding.
The benazepril group received benazepril hydrochlorideb PO
at a dosage of 0.25–0.5 mg/kg once a day. In keeping with the
manufacturer’s recommendations, at the discretion of the investi-
gator, the benazepril dose could be doubled. This involved the
investigator instructing the dispenser, “If the dog is receiving
benazepril, please double the dose,” thus ensuring the investiga-
tor remained blinded as to treatment allocation of the case. The
time of such a request was recorded and regarded as an intended
intensification of treatment. The dosage was adjusted to a suit-
able number of 5 mg tablets.
Concomitant Treatments. Standard concomitant treatment for
heart failure (such as diuretics and digoxin) was permitted
throughout the trial with the following restrictions: open label
use of pimobendan, benazepril, or any other ACE-I was pre-
cluded as was the use of phenylalkylamine calcium channel
antagonists, xanthines, or angiotensin II receptor antagonists. In
cases where dogs were already receiving an ACE-I or pimoben-
dan treatment at inclusion, these drugs were discontinued imme-
diately before allocation to either of the 2 test treatments.
Dosages of concomitant treatments could be modified, if needed,
throughout the study. The time and nature of any change in
concomitant treatment were recorded.
Schedule of Events. Before inclusion, the case history of each
dog was ascertained and any previous documentation of the case
was reviewed (eg, radiographs, laboratory results). The dogs then
underwent physical examination, electrocardiography (ECG), echo-
cardiography, thoracic radiography, and routine hematology and
blood biochemistry with a minimal database consisting of packed
cell volume (PCV) and plasma total protein concentration (TPC),
and serum creatinine, potassium, and sodium concentrations.
Scheduled reexaminations were at day 7, day 28, and
3 months after inclusion. Thereafter, the dogs were scheduled for
reexamination every 3 months. On every visit, the following
occurred: a case history was obtained including recording the
type and dose of each medication the dog was receiving, a com-
plete physical examination was performed, an ECG was
recorded, and blood was taken to measure PCV, TPC, and serum
creatinine, sodium, and potassium concentrations. Echocardiog-
raphy and thoracic radiographic examinations were scheduled
every 6 months after inclusion.
Clinical Evaluation. At inclusion, canine characteristics were
recorded. The time since onset of clinical signs and the duration,
type, and efficacy of any pretreatment were recorded. At each
examination, body weight and rectal temperature were measured.
Quality of Life and Respiratory Variables. After history taking
and clinical examination, the following variables were scored
according to the system outlined in Table 1: appetite, demeanor,
exercise tolerance, respiratory effort, coughing, and nocturnal
dyspnea.
Heart Rate and ECG. The resting heart rate was measured
during the physical examination. A 3-minute ECG recording was
performed with the dogs lying in right lateral recumbency. Each
dog’s cardiac rhythm was classified as showing sinus rhythm,
extrasystoles (ventricular or supraventricular or both), or atrial
fibrillation (AF).
Echocardiography. Echocardiography was used to confirm the
diagnosis of MMVD before inclusion and, thereafter to monitor
disease progression. The following measurements were recorded:
Table 1. Scoring protocol for clinical variables.
Variable Score Clinical Correlate
Exercise
tolerance
1 (Very
good)
Dog moved around with ease,
was able to fully exercise
2 (Good) Dog moved around with ease, was
not able to fully exercise; ability
to run was reduced
3 (Moderate) Dog was less active than normal,
moved around a few times per
day, avoided long walks
4 (Poor) Dog was inactive and would only
get up to eat, drink, or urinate
Demeanor 1 Alert, responsive
2 Mildly depressed
3 Moderately depressed
4 Minimally responsive
5 Unresponsive
Appetite 1 Increased
2 Normal
3 Decreased (2/3 normal)
4 Markedly decreased (<2/3 normal)
Respiratory
effort
1 Normal
2 Mildly increased rate or effort
3 Moderately labored
4 Severe respiratory distress
Coughing 1 None
2 Occasional (a few times a week)
3 Frequent (a few times a day)
4 Persistent (frequently during
the day)
Nocturnal
dyspnea
1 None
2 Dog coughed from time to
time during the night, but no
other clinical signs of dyspnea
or restlessness were present
3 Dog coughed consistently;
increased respiratory effort
or restlessness during the night
Pulmonary
edema
1 None
2 Mild interstitial opacity
3 Moderate interstitial opacity
4 Alveolar pattern,
severe consolidation
Modified
NYHA
heart failure
score16
I Asymptomatic dogs with murmur,
but no cardiac enlargement
II Asymptomatic dogs with murmur
and cardiac enlargement, but
no pulmonary edema or
congestion
III Slightly or moderately
symptomatic dogs (dyspnea),
increased heart rate and
disappearance of sinus
arrhythmia) with murmurs,
cardiac enlargement, and
interstitial pulmonary edema
IV Severely symptomatic dogs with
murmurs, cardiac enlargement,
and alveolar pulmonary edema
NYHA, New York Heart Association.
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the LA/Ao ratio obtained from the right parasternal short axis
2-dimensional (2D) view as previously described.12 The LVIDd
and left ventricular internal diameter in systole (LVIDs) were
measured from the M-mode echocardiogram, which was obtained
from the right parasternal short-axis 2D view.15 M-mode
values were used to derive the percent increase in LVIDd
(LVIDd inc) and LVIDs (LVIDs inc) as follows: %
increase = [100 9 (observed dimension  expected normal
dimension)/expected normal dimension] and the fractional short-
ening (FS). Expected normal dimensions based on body weight
(BW) were calculated as previously described.13
Thoracic Radiography. Thoracic radiography was used to con-
firm the presence of cardiomegaly and pulmonary edema, to
exclude concurrent disease at inclusion into the study, and to
measure cardiac dimensions. Right lateral and dorsoventral
projections were used to evaluate the thorax. Cardiomegaly was
assessed with the VHS method14 and pulmonary edema if present
was scored (Table 1).
Heart Failure Score. The modified New York Heart Associa-
tion (NYHA) score was used to score the severity of heart failure
(Table 1).16
Endpoints. Dogs were considered to have reached the primary
endpoint of the QUEST trial only when one of the following
occurred: sudden cardiac death, euthanasia as a consequence of
the cardiac disease, or treatment failure leading to the clinician
withdrawing the dog from the trial.5 Dogs were censored if they
died or were euthanized because of noncardiac causes, were lost
to follow-up, or were alive and had not reached the primary end-
point at the termination of the study.
Time from randomization to the 1st increase in dose of any
treatment or the introduction of any permitted additional con-
comitant treatment (as outlined above) after enrollment in the
study was considered as a secondary endpoint and referred to as
intensification of CHF treatment. For this secondary endpoint,
dogs in which no intensification of their treatment had occurred
during the study were censored, which included dogs that had
reached the primary endpoint without undergoing any intensifica-
tion of their treatment.
Outcome Measure. The primary outcome measure of the
QUEST trial was the time from randomization to withdrawal
because of death or euthanasia owing to cardiac causes or treat-
ment failure.
Secondary outcome measures included values of QoL, clinical,
radiographic, echocardiographic, and laboratory variables mea-
sured over the duration of the study and time from randomiza-
tion to any increase in dose of any treatment, or the introduction
of any permitted additional concomitant treatment (as outlined
above) after enrollment in the study.
Statistical Methods
For every dog for which any of the QoL, clinical, radio-
graphic, echocardiographic, and laboratory variables was mea-
sured on ≥1 occasions after baseline assessment, a curve was
constructed by plotting each data point on a graph with the unit
of measurement on the vertical axis and time on the horizontal
axis. The area under the curve averaged for the number of days
between the 1st and last observation was calculated thus giving
an average value for the variable that incorporated all of the
observations made and was independent of the duration of time
the dog remained in the study.17 These derived variables were
used as summary measures of the values of the variable over the
time in study for each dog. These values then were compared
between treatment groups using the Wilcoxon rank sum test.17
The proportions of dogs in each treatment group experiencing
modifications in the dose, or addition of the drugs furosemide,
spironolactone, or digoxin, or in which the investigator expressed
an intention to increase the benazepril dosage, at the time of the
1st intensification of treatment, were compared using the Fisher’s
exact test. Furthermore, the proportion of dogs in each treatment
group receiving spironolactone and the proportion of dogs in
each treatment group receiving digoxin at each scheduled visit
were compared using the Fisher’s exact test.
A log-rank test with right censoring was used to determine
whether a significant difference existed between the 2 treatment
groups for the variable “time from randomization to the first
increase in dosage of any treatment, or the introduction of any
permitted additional concomitant treatment after enrollment in
the study.” The Kaplan–Meier method was used to estimate the
median time to this secondary endpoint for each treatment group
and plot time to event curves. In addition, univariate and multi-
variate Cox proportional hazards analyses with right censoring
were performed to determine whether there was a significant dif-
ference between treatment groups. The hazard ratio with 95%
confidence intervals was calculated.
For all analyses, a P value <.05 was considered significant. All
analyses were 2-tailed. Median values and interquartile (IQR)
ranges are reported. All statistical analyses were performed by an
independent statisticianc using a commercially available software
program.d
Results
The study population (Table 2), event rate, and
effect of baseline variables and treatment on the time
to composite primary endpoint have been described
previously.5 Pertinent details are repeated below.
Two hundred and sixty dogs were recruited; 8 dogs
were excluded from further analysis after termination
of the trial, but before unblinding. Of the 252 dogs
analyzed (116 males, 38 females, 37 neutered males,
and 61 neutered females), the most commonly
recruited breed was the CKCS (n = 82). One hundred
and twenty-four dogs were randomized to the pimob-
endan group and 128 dogs to the benazepril group.
One hundred and ninety dogs (75%) reached the
primary endpoint; 62 dogs (25%) were censored. No
dogs were lost to follow-up.
Effect of Treatment over Time (AUC adjusted for
days in study) and Incidence of Arrhythmias
The results of the comparisons of QoL, clinical, lab-
oratory, radiographic, and echocardiographic variables
between groups over time are illustrated in Table 3.
The following variables were significantly higher in the
dogs receiving pimobendan: rectal temperature, serum
sodium concentration, PCV, and TPC. The following
variables were significantly lower in the dogs receiving
pimobendan: VHS, LVIDs inc, and LVIDd inc (also
LVIDd and LVIDs). There was no difference in inci-
dence of new arrhythmias between the treatment
groups (Table 4).
Effect of Treatment Group on Concurrent Treatment
The proportions of dogs and the nature of the change
in treatment required at the time of modification that
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were first deemed as necessary were no different in the
2 treatment groups (Table 5). Only 6 dogs (4 dogs in
the benazepril group and 2 in the pimobendan group)
had an intended intensification of heart failure treat-
ment consisting only of a desire to increase the bena-
zepril dosage. Intensifications in all other dogs for
which the investigator expressed a desire to increase
the benazepril dosage consisted of a change in at least
1 additional drug. A significantly greater proportion of
dogs received spironolactone treatment in the benazep-
ril group at 28 days, 3 months, and 6 months and a
significantly greater proportion of dogs received
digoxin treatment in the benazepril group at 3 months
(Table 6).
Of the 252 dogs included in the study, there was an
intensification of heart failure treatment in 172 dogs
(83 dogs in the pimobendan group and 89 in the bena-
zepril group), whereas 80 dogs (41 dogs in the pimob-
endan group and 39 in the benazepril group) were
censored in the statistical analyses. The proportions of
censored dogs in the 2 treatment groups were not sig-
nificantly different (P = .69), whereas the time in the
study to censoring was significantly longer in the
pimobendan group compared with the benazepril
group (median, 123 days; IQR, 19.5–372 days versus
median, 39 days; IQR, 26–92 days; P = .038). Dogs
receiving pimobendan had a significantly longer time
period (median, 98 days; IQR, 30–276 days) before
experiencing any intensification in their treatment
compared with those receiving benazepril (59 days;
IQR, 11–121 days; Fig 1; P = .0005). This significant
difference persisted (P = .014) if the desire to increase
benazepril dosage was not considered as an intensifica-
tion of heart failure treatment. Dogs receiving bena-
zepril were 1.69 times more likely to undergo
intensification of their treatment first (hazard ratio,
1.69; 95%, CI, 1.24–2.29; P = .0008) in the univariate
analysis. This difference persisted after adjusting for
all baseline variables in the multivariate Cox propor-
tional hazard analysis.
Table 2. Summary of baseline characteristics in the 2 treatment groups (frequencies or medians [IQR]).
Variable Pimobendan (N = 124) Benazepril (N = 128) P Value
Canine characteristics
Age (years) 10.0 (8.0–11.0) 10.0 (8.0–12.0) .06
Sex (M/F/MC/FN) 59/14/24/27 57/24/13/34 .08
Cavalier (yes/no) (%) 34/90 (27/73%) 48/80 (38/62%) .09
Treatment
Furosemide dose (mg/kg/day) 4.7 (3.4–6.7) 4.4 (3.0–6.4) .18
Digoxin (yes/no) 16/108 27/101 .10
Spironolactone (yes/no) 21/103 24/104 .74
Quality of life and respiratory variables
Appetite 2.0 (2.0–3.0) 2.0 (2.0–3.0) .95
Demeanor 1.0 (1.0–2.0) 1.0 (1.0–2.0) .61
Exercise tolerance 2.0 (2.0–3.0) 2.0 (2.0–3.0) .62
Respiratory effort 2.0 (1.2–3.0) 2.0 (1.0–3.0) .84
Cough 3.0 (2.0–3.0) 3.0 (2.0–3.0) .32
Nocturnal coughing 2.0 (1.0–3.0) 2.0 (1.0–3.0) .74
Physical examination
Rectal temperature (°C) 38.5 (38.2–38.9) 38.5 (38.2–38.9) .42
Heart rate (bpm) 144 (126–162) 148 (128–165) .54
Body weight (kg) 9.0 (6.9–11.4) 9.5 (7.6–11.7) .18
HF score 3.0 (3.0–3.0) 3.0 (3.0–3.0) .97
Diagnostic imaging
VHS score 12.5 (11.5–13.0) 12.5 (12.0–13.5) .15
PE score 2.5 (1.0–5.0) 3.0 (1.0–5.0) .65
LVIDs inc (%) 19.7 (4.0–37.0) 24.5 (10.7–43.4) .08
LVIDd inc (%) 42.9 (30.0–57.6) 45.5 (33.8–58.6) .40
FS (%) 45 (41–50) 44 (39–48) .09
LA/Ao 2.4 (2.0–2.7) 2.3 (2.0–2.7) .61
Laboratory variables
Na (mmol/L) 148 (145–151) 148 (146–150) .65
K (mmol/L) 4.4 (3.9–4.9) 4.3 (3.9–4.8) .53
PCV (%) 45.2 (42–51) 46.0 (41–50) .39
Creatinine (mg/dL) 1.0 (0.8–1.1) 1.0 (0.8–1.2) .38
TPC (g/dL) 6.5 (6.0–7.0) 6.4 (6.0–7.0) .72
IQR, interquartile range; M, male; F, female; MC, male castrated; FN, neutered female; bpm, beats per minute; HF, heart failure;
VHS, vertebral heart scale; PE, pulmonary edema; LVIDs, left ventricular internal diameter in systole; LVIDs inc, percentage increase
in left ventricular internal diameter in systole from expected values; LVIDd, left ventricular internal diameter in diastole; LVIDd inc,
percentage increase in left ventricular internal diameter in diastole from expected values; FS, fractional shortening; LA/Ao, left atrial to
aortic root ratio; K, potassium; Na, sodium; PCV, packed cell volume; TPC, total protein concentration.
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Discussion
The current report shows that in dogs receiving con-
current heart failure treatment, pimobendan when
compared with benazepril treatment results in a similar
QoL for the duration of the period of treatment, but
increases the time period before it is necessary to
intensify treatment, which, in turn, leads to a lower
proportion of dogs receiving additional heart failure
drugs. Furthermore, dogs receiving pimobendan had
smaller heart size and higher body temperature, serum
sodium concentration, TPC, and PCV by comparison
to dogs receiving benazepril.
Quality of life is defined in people as a reflection of
the way a person’s mental and physical well-being is
evident in their everyday life.18 One of the main ways
in which heart failure and its treatment affects QoL is
through its impact on people’s ability to perform their
normal daily activities.19 In some studies, QoL is
Table 3. Median AUC adjusted for days in study and IQR for dogs treated with pimobendan and dogs treated
with benazepril.
Variable Treatment N Median IQR
P Value
Wilcoxon
Quality of life and
respiratory variables
(see Table 1 for levels)
Appetite Pimobendan 118 2.0 1.9–2.1 .12
Benazepril 124 2.0 2.0–2.30
Cough Pimobendan 118 2.3 1.6–2.9 .71
Benazepril 124 2.3 1.9–2.8
Demeanor Pimobendan 118 1.2 1.0–1.5 .86
Benazepril 124 1.2 1.0–1.5
Exercise tolerance Pimobendan 118 2.0 1.6–2.4 .73
Benazepril 124 2.0 1.6–2.4
Nocturnal dyspnea Pimobendan 118 1.4 1.0–2.0 .54
Benazepril 124 1.4 1.0–2.0
Respiratory effort Pimobendan 118 1.5 1.1–2.0 .47
Benazepril 124 1.7 1.2–2.0
Furosemide dose Furosemide dose (mg/kg/day) Pimobendan 117 4.8 3.4–6.6 .69
Benazepril 121 5.1 3.7–6.8
Physical examination Rectal temperature (°C) Pimobendan 118 38.6 38.3–38.8 .029
Benazepril 124 38.5 38.2–38.7
Heart rate (bpm) Pimobendan 118 137.6 128.1–151.8 .32
Benazepril 124 140.9 128.6–156.8
Body weight (kg) Pimobendan 118 9.0 7.1–11.3 .29
Benazepril 124 9.4 7.6–11.6
HF score Pimobendan 118 2.5 2.0–3.0 .44
Benazepril 124 2.5 2.1–3.0
Diagnostic imaging VHS score Pimobendan 69 12.4 11.5–13.0 .013
Benazepril 49 12.9 11.9–13.8
Severity of PE (scores 1–5) Pimobendan 69 2.0 1.5–2.5 .81
Benazepril 49 2.0 1.5–2.5
LVIDs inc (%) Pimobendan 67 15.2 0.6–24.7 .0044
Benazepril 49 24.3 14.6–39.0
LVIDd inc (%) Pimobendan 67 36.3 28.4–50.9 .035
Benazepril 49 46.5 33.0–61.1
FS (%) Pimobendan 69 46.5 42.5–48.8 .11
Benazepril 49 44.5 40.3–48.4
LA/AO Pimobendan 69 2.2 1.9–2.6 .83
Benazepril 49 2.3 2.0–2.6
Laboratory variables Na (%) Pimobendan 117 148.7 146.2–150.7 .0027
Benazepril 120 147.0 144.7–149.5
K (mmol/L) Pimobendan 117 4.3 3.9–4.7 .92
Benazepril 120 4.3 3.9–4.8
PCV (%) Pimobendan 117 46.8 42.8–50.9 .030
Benazepril 120 45.5 40.5–49.3
Creatinine (mg/dL) Pimobendan 117 1.1 0.9–1.287 .58
Benazepril 120 1.1 0.907–1.4
TPC (g/dL) Pimobendan 117 6.7 6.4–7.2 .0003
Benazepril 119 6.5 6.0–6.9
AUC, area under curve; IQR, interquartile range; bpm, beats per minute; HF, heart failure; VHS, vertebral heart scale; PE, pulmo-
nary edema; LVIDs, left ventricular internal diameter in systole; LVIDs inc, percentage increase in LVIDs from expected values; LVIDd,
left ventricular internal diameter in diastole; LVIDd inc, percentage increase in LVIDd from expected values; FS, fractional shortening;
LA/Ao, left atrial to aortic root ratio; K, potassium; Na, sodium; PCV, packed cell volume; TPC, total protein concentration.
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considered the most important outcome in symptom-
atic people with heart failure even surpassing quantity
of life.20 Comparatively little work has evaluated the
assessment of QoL in veterinary cardiac patients or
addressed the importance of preservation of QoL in
the face of terminal disease. A recent study demon-
strated that owners of dogs with heart disease place a
high value on preservation of QoL and, in fact, most
of these owners valued preservation of QoL over
survival.6
The area under the curve approach used in this
report is, in this setting, a novel method to deal with
missing data and variable periods of follow-up. This
technique has been used previously for the analysis of
longitudinal data in veterinary studies.21 The summary
statistic (area under the curve) was used to compare
QoL and other indices between treatment groups. This
technique has the advantage that data from every visit
of every dog for which longitudinal measurements are
available can be included and yet it reduces the values
of the variable over multiple observations to a single
index. It does not require comparisons between groups
at multiple time points (repeated measures analysis), a
technique with statistical limitations.17 Finally, it does
not require the carrying forward of any data for dogs
that have already reached the primary endpoint, a
technique which may bias the outcome when there is
an unequal rate of removal from the study.22
In studies in which determination of the effect of a
drug on QoL is a primary aim, it is necessary to main-
tain background treatment at a constant level to iden-
tify differences between groups as a consequence of the
drug being studied.23 In long-term studies, it is not eth-
ically acceptable to deny modification in background
treatment to patients, particularly those that are doing
poorly. It has been argued that intensification of treat-
ment represents evidence of a patient’s condition wors-
ening.24 Recognition of this fact has been employed in
developing a composite index of a patient’s overall
experience in heart failure trials in humans referred to
as the “Patient Journey.”24,25 This index was used in
the COMET trial and patients in whom treatment was
intensified were considered to score 1 rank worse than
those in whom intensification was not required.25
We examined the necessity for intensification of con-
current treatment in patients in the QUEST study by
looking at the time to intensification of treatment and
the frequency of use of common concurrent medica-
tions. We presumed that the reason an investigator
decided to increase the dosage of one or more of the
baseline therapies or to add another agent was because
he or she believed the dog would benefit from the
change because of a deterioration in the condition of
the dog or the owner being concerned that their pet
was failing to achieve an adequate QoL on their
current treatment regimen.
Thus, although the average values for QoL variables
were found to be similar in the 2 treatment groups
over the duration of the study, dogs in the benazepril
group required intensification of treatment earlier to
maintain their QoL. The intensification of heart failure
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treatment could consist of more than 1 change in the
medication. Among several possible changes in medi-
cation in this study, the investigators had the opportu-
nity to indicate that an increase in benazepril dosage
was desired, and this was considered an intensification
of the treatment. Because dogs in the pimobendan
group could not receive this intensification of treat-
ment, this potentially could be a confounder in this
study. However, only 6 dogs (4 in the benazepril and 2
in the pimobendan group) had an intended increase in
benazepril dosage as the only intensification. All other
dogs had a change (intensification) in more than 1
drug. Furthermore, the significant difference in time to
intensification persisted after having ignored a desire
to increase benazepril dosage as an intensification of
heart failure treatment. The similarity of QoL in the 2
groups is therefore probably a consequence of investi-
gators being at liberty to modify medication to main-
tain an acceptable QoL for their patients. As we have
already shown, the administration of pimobendan was
associated with a prolongation of survival5 and this
analysis suggests that dogs receiving pimobendan have
a longer life of a similar quality. We also can conclude
that this prolongation of survival was achieved without
the need for more intensive treatment. In fact, it
appears that dogs in the benazepril group required
alteration of their treatment sooner and more frequent
administration of other medications (eg, spironolac-
tone, digoxin) to maintain the same QoL. We consider
this finding clinically relevant because one of the goals
of treating any condition (and especially CHF) in view
of maintaining a good QoL is to do so with the fewest
number of different drugs necessary. Polypharmacy
has the potential to decrease owner compliance,
increases the risk of accidental dosage errors and omis-
sion of drug administration by the owner, and
increases the total cost of treatment.
In addition to the QoL indices, we also compared
clinical, radiographic, echocardiographic, and labora-
tory variables between the groups of dogs in our study
using the area under the curve statistic. We found that
7 variables differed significantly between the pimoben-
dan and benazepril groups over the duration of the
study. One was rectal temperature, 3 were indicators
of heart size (VHS, LVIDs inc, and LVIDd inc) and 3
were blood constituents (TPC, PCV, and serum
sodium concentration). Rectal temperature previously
has been shown in Doberman Pinschers with heart
failure secondary to dilated cardiomyopathy to be an
independent predictor of outcome.26 In human heart
failure patients, low body temperature at time of hos-
pital admission27 and decreasing body temperature
over time28 both are predictors of poor outcome. The
median values of rectal temperature were within the
normal reference range for dogs in both treatment
groups with a difference of 0.1°C. Although this differ-
ence between treatment groups was statistically signifi-
cant (P = .030), it is too small a change to be of
clinical value in monitoring individual patients. It has
been speculated that lower body temperature may be a
result of lower cardiac output,26 and the small differ-
ence between our treatment groups may have been
because of improved perfusion in the pimobendan
group.
Differences in heart size between groups of dogs
treated with pimobendan and dogs receiving an ACE-I
have been demonstrated previously.9,29 Several mecha-
nisms could be responsible for changes in heart size.
The reduction in vascular resistance and enhancement
of cardiac contractility achieved with an inodilator
may allow the heart to contract down to a smaller
end-systolic diameter and maintain an adequate stroke
volume with a lower end-diastolic diameter. A larger
ventricular diameter will be directly associated with an
increase in systolic wall stress and worse secondary
mitral regurgitation, and may therefore be associated
with worse outcome.30,31
Three of the variables that differed significantly
between groups were blood constituents: TPC, PCV,
and serum sodium concentration. Over the period of
time that dogs spent in the study, the median values
for these variables differed by only a relatively small
amount and neither group had a median value outside
the reference range, but median values were consis-
tently lower in the benazepril group (1.6 mmol/L lower
sodium concentration, 1.2% lower PCV, and 0.2 g/dL
lower TPC; P = .0027, P = .0299, and P = .0003,
respectively). Although these differences between treat-
ment groups were statistically significant, they are too
small to be of clinical value in monitoring individual
Table 5. Number and proportion of all dogs in the 2 treatment groups that underwent intensification of heart
failure treatment and the number and proportion of those dogs that underwent a change, that experienced the 4
most common changes. Notice that dogs could experience an intensification of heart failure treatment consisting
of more than one change.
Pimobendan (%) Benazepril (%) P Value
Change in treatment 83/124 (67) 89/128 (70) .69
Nature of 1st treatment change
Increased furosemide dose 71/83 (86) 77/89 (87) 1.0
Added spironolactone 43/83 (52) 55/89 (62) .21
Indicated desire to increase ACE-inhibitor dosea 20/83 (24) 31/89 (35) .14
Added digoxin 16/83 (19) 23/89 (26) .36
aA desire to increase the ACE-inhibitor dose, without any other changes to the medication, occurred in 4 dogs in the benazepril group
and 2 dogs in the pimobendan group.
1448 Ha¨ggstro¨m et al
patients. These differences, however, are unlikely to be
caused by hemoconcentration in the pimobendan
group because the furosemide dosage and serum creat-
inine concentrations were similar in the treatment
groups. Hyponatraemia,32 hypoalbuminemia,33 and
anemia34 all have been shown to be independent pre-
dictors of poor outcome in human heart failure
patients, although this has not been demonstrated in
veterinary patients.
There are multiple factors that can lead to altera-
tions in PCV and TPC in heart failure, including
hemodilution, malnutrition, and chronic inflamma-
tion.33,34 In the absence of unmeasured osmoles (eg,
glucose), the most likely reason for a decrease in serum
sodium concentration is an excess of free water reten-
tion (or failure of free water clearance), which occurs
either in the presence of sodium depletion or in isola-
tion.35 The combination of higher serum sodium
concentration, plasma proteins, and PCV in dogs
receiving pimobendan suggests that there may be
decreased free water retention or improved free water
excretion associated with the administration of this
agent in comparison with the administration of bena-
zepril. Increasing serum sodium concentrations have
been shown to indicate a more favorable prognosis in
hospitalized human heart failure patients.36,37 To our
knowledge, ours is the 1st veterinary study showing
differences in PCV, TPC, and serum sodium concen-
trations arising from differences in the administration
of standard heart failure therapies.
Our electrocardiographic findings suggest that the
pimobendan and benazepril groups had a similar
frequency of onset of new arrhythmias. This finding
indicates that neither treatment was associated with anT
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Fig 1. Kaplan–Meier plot of percentage dogs with no intensifi-
cation of heart failure therapy as a function of time in 124 dogs
treated with pimobendan and in 128 dogs treated with benazep-
ril. Dogs receiving pimobendan had a significantly longer time
period (median, 98 days; IQR, 30–276 days) before experiencing
any intensification in their treatment compared to those receiving
benazepril (median, 59 days; IQR, 11–121 days; P = 0.0005).
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increased likelihood of development of arrhythmia in
dogs with advanced MMVD.
Limitations
As with the original report,5 the principal limitation
is the single-blinded nature of the study. Owners were
aware of the medication used on their pets, whereas
the investigators were not. The risk with a single-
blinded design is that the unblinded party (the owner)
may influence the outcome based on some precon-
ceived or acquired sense that one treatment may be
superior to the other. QoL variables are inherently
subjective and so it is possible that this design may
affect these variables more than objective variables.
The area under the curve statistic uses 1 value for
the variable measured over multiple time points. How-
ever, the time points were not equally distributed in
time. Thus, variations in values in the first 30 days
could have more influence on the summary statistic
than later observations.
The method of acquiring the QoL data used in this
study has not been analyzed with respect to validity,
reliability, and responsiveness as a metric tool. The use
of the FETCH questionnaire38 may have enabled the
detection of more subtle differences between treatment
groups. However, this particular instrument was not
available at the time the QUEST study was designed
and has yet to be fully evaluated in the setting of a
large clinical trial.
Conclusions
Pimobendan plus conventional treatment compared
with benazepril plus conventional treatment resulted in
similar QoL during the study, but conferred an
increased time before intensification of heart failure
treatment was deemed necessary, leading to a lower
proportion of dogs receiving additional treatments at
certain time points. Pimobendan treatment also was
associated with a smaller heart size, higher body temper-
ature, and less tendency to retain free water, as indicated
by certain laboratory variables. There was no difference
in arrhythmia incidence between treatment groups.
Footnotes
a Vetmedin; Boehringer Ingelheim Vetmedica, Ingelheim,
Germany
b Fortekor; Novartis Animal Health, Basel, Switzerland
c Dr Martin Vanselow; Biometrie & Statistik, Hannover, Ger-
many
d SAS Version 8.2; SAS Institute Inc., Cary, NC
Acknowledgments
The investigators are grateful to Boehringer Ingelheim
Animal Health GmbH for funding the study, and we
thank the small animal hospitals involved and the
schools of veterinary medicine for their efforts and sup-
port enabling successful completion of the study. We
also thank all canine owners for their excellent coopera-
tion and willingness to contribute with their dogs.
Conflict of Interest Declarations: The study was
funded by Boehringer Ingelheim Animal Health
GmbH. The sponsor granted the investigators the right
to publish the results, regardless of outcome. Olaf Jo¨ns
is an employee of Boehringer Ingelheim Animal Health
GmbH. All other authors have received funding from
Boehringer Ingelheim within the last 5 years for some
or all of the following activities: research, travel,
speaking fees, consultancy fees, and preparation of
educational materials.
References
1. Borgarelli M, Savarino P, Crosara S, et al. Survival charac-
teristics and prognostic variables in canine mitral regurgitation
attributable to myxomatous valve disease in dogs. J Vet Intern
Med 2008;22:120–128.
2. Buchanan J. Prevalence of cardiovascular disorders. In:
Fox P, Sisson D, Moise N, eds. Canine and Feline Cardiology,
2nd ed. Philadelphia, PA: WB Saunders; 1999:457–470.
3. Ha¨ggstro¨m J, Pedersen H, Kvart C. New insights into
degenerative mitral valve disease in dogs. Vet Clin North Am
Small Anim Pract 2004;34:1209–1226.
4. Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of ena-
lapril maleate on survival of dogs with naturally acquired heart
failure. J Am Vet Med Assoc 1998;213:1573–1577.
5. Ha¨ggstro¨m J, Boswood A, O’Grady M, et al. Effect of
pimobendan or benazepril hydrochloride on survival times in
dogs with congestive heart failure caused by naturally occurring
myxomatous mitral valve disease: The QUEST study. J Vet
Intern Med 2008;22:1124–1135.
6. Oyama MA, Rush JE, O’Sullivan ML, et al. Perceptions
and priorities of owners of dogs with heart disease regarding
quality versus quantity of life for their pets. J Am Vet Med
Assoc 2008;233:104–108.
7. The BENCH Study Group. The effect of benazepril on sur-
vival times and clinical signs of dogs with congestive heart
failure: Results of a multicenter, prospective, randomized, dou-
ble-blinded, placebo-controlled, long-term clinical trial. J Vet
Cardiol 1999;1:7–18.
8. The COVE Study Grup. Controlled clinical evaluation of
enalapril in dogs with heart failure: Results of the coperative vet-
erinary enalapril study group. J Vet Intern Med 1995;9:243–252.
9. Lombard C, Jo¨ns O, Bussadori C. Clinical efficacy of
pimobendan versus benazepril for the treatment of acquired
atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc
2006;42:249–261.
10. Smith P, French A, Van Isra€el N, et al. Efficacy and safet
of pimobendan in canine heart failure caused by myxomatous
mitral valve disease. J Small Anim Pract 2005;46:121–130.
11. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the
diagnosis and treatment of canine chronic valvular heart disease.
J Vet Intern Med 2009;23:1142–1150.
12. Hansson K, Ha¨ggstro¨m J, Kvart C, et al. Left atrial to
aortic root root indices using two-dimensional and M-mode
echocardiography in dogs with and without left atrial enlarge-
ment. Vet Radiol Ultrasound 2002;43:568–757.
13. Cornell C, Kittleson M, Della Torre P, et al. Allometric
scaling of M-mode cardiac measurements in normal adult dogs.
J Vet Intern Med 2004;18:311–321.
1450 Ha¨ggstro¨m et al
14. Buchanan J, Bucheler J. Vertebral scale system to measure
canine heart size in radiographs. J Am Vet Med Assoc
1995;206:194–199.
15. Kienle RD, Thomas WP. Veterinary diagnostic ultra-
sound. In: Nyland TG, Mattoon JS, eds. Echocardiography.
Philadelphia, PA: W.B. Saunders; 1995:198–255.
16. Kvart C, Haggstrom J, Pedersen HD, et al. Efficacy of
enalapril for prevention of congestive heart failure in dogs with
myxomatous valve disease and asymptomatic mitral regurgita-
tion. J Vet Intern Med 2002;16:80–88.
17. Matthews JN, Altman DG, Campbell MJ, et al. Analysis of
serial measurements in medical research. BMJ 1990;300:230–235.
18. Dunderdale K, Thompson DR, Miles JN, et al. Quality-
of-life measurement in chronic heart failure: Do we take account
of the patient perspective? Eur J Heart Fail 2005;7:572–582.
19. Leidy NK, Rentz AM, Zyczynski TM. Evaluating health-
related quality-of-life outcomes in patients with congestive heart
failure. A review of recent randomised controlled trials. Pharm
Econ 1999;15:19–46.
20. Stanek EJ, Oates MB, McGhan WF, et al. Preferences for
treatment outcomes in patients with heart failure: Symptoms
versus survival. J Card Fail 2000;6:225–232.
21. Jepson RE, Elliott J, Brodbelt D, et al. Effect of control
of systolic blood pressure on survival in cats with systemic hyper-
tension. J Vet Intern Med 2007;21:402–409.
22. Lane P. Handling drop-out in longitudinal clinical trials:
A comparison of the LOCF and MMRM approaches. Pharm
Stat 2008;7:93–106.
23. Packer M. Proposal for a new clinical end point to evalu-
ate the efficacy of drugs and devices in the treatment of chronic
heart failure. J Card Fail 2001;7:176–182.
24. Cleland JG. How to assess new treatments for the man-
agement of heart failure: Composite scoring systems to assess the
patients’ clinical journey. Eur J Heart Fail 2002;4:243–247.
25. Cleland JG, Charlesworth A, Lubsen J, et al. A compari-
son of the effects of carvedilol and metoprolol on well-being,
morbidity, and mortality (the “patient journey”) in patients with
heart failure: A report from the Carvedilol Or Metoprolol Euro-
pean Trial (COMET). J Am Coll Cardiol 2006;47:1603–1611.
26. O’Grady MR, Minors SL, O’Sullivan ML, et al. Effect of
pimobendan on case fatality rate in Doberman Pinschers with
congestive heart failure caused by dilated cardiomyopathy. J Vet
Intern Med 2008;22:897–904.
27. Nallamothu BK, Payvar S, Wang Y, et al. Admission
body temperature and mortality in elderly patients hospitalized
for heart failure. J Am Coll Cardiol 2006;47:2563–2564.
28. Ahmed A, Aboshady I, Munir SM, et al. Decreasing body
temperature predicts early rehospitalization in congestive heart
failure. J Card Fail 2008;14:489–496.
29. Wolley R, Smith P, Munro E, et al. Effect of treatment
type on vertebral heart size in dogs with myxomatous mitral
valve disease. Intern J Appl Res Vet Med 2007;5:43–48.
30. Gaasch WH, Meyer TE. Left ventricular response to
mitral regurgitation: Implications for management. Circulation
2008;118:2298–2303.
31. Summerfield NJ, Boswood A, O’Grady MR, et al. Effi-
cacy of pimobendan in the prevention of congestive heart failure
or sudden death in Doberman Pinschers with preclinical dilated
cardiomyopathy (the PROTECT Study). J Vet Intern Med
2012;26:1337–1349.
32. De Luca L, Klein L, Udelson JE, et al. Hyponatremia in
patients with heart failure. Am J Cardiol 2005;96:19L–23L.
33. Horwich TB, Kalantar-Zadeh K, MacLellan RW, et al.
Albumin levels predict survival in patients with systolic heart fail-
ure. Am Heart J 2008;155:883–889.
34. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia
is associated with worse symptoms, greater impairment in func-
tional capacity and a significant increase in mortality in patients
with advanced heart failure. J Am Coll Cardiol 2002;39:1780–
1786.
35. Adrogue HJ, Madias NE. Hyponatremia. New Eng J Med
2000;342:1581–1589.
36. Goldsmith SR. Current treatments and novel pharmaco-
logic treatments for hyponatremia in congestive heart failure. Am
J Cardiol 2005;95:14B–23B.
37. Rossi J, Bayram M, Udelson JE, et al. Improvement in
hyponatremia during hospitalization for worsening heart failure
is associated with improved outcomes: Insights from the acute
and chronic therapeutic impact of a vasopressin antagonist in
chronic heart failure (ACTIV in CHF) trial. Acute Card Care
2007;9:82–86.
38. Freeman LM, Rush JE, Farabaugh AE, et al. Develop-
ment and evaluation of a questionnaire for assessing health-
related quality of life in dogs with cardiac disease. J Am Vet
Med Assoc 2005;226:1864–1868.
Pimobendan for Myxomatous Mitral Valve Disease 1451
